Peptides DB
Research-centric peptide and protocol reference hub

Cagrilintide (AM833) record · updated 4h ago

Metabolic & appetiteSkin & aestheticsGrade A · human clinicalResearch use only
All 19 studiesJump to the evidenceCompare
What is Cagrilintide (AM833) used for?

Cagrilintide (AM833) is a long-acting amylin analog investigated for once-weekly subcutaneous use in obesity and type 2 diabetes, most notably combined with semaglutide as CagriSema.

How it works: Long-acting amylin analog

Primarily researched for · Metabolic & appetiteRoute · Subcutaneous injection

Development stage

where Cagrilintide (AM833) sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Cleared
    Phase 1
    Safety in humans
  3. 3Cleared
    Phase 2
    Efficacy signal
  4. 4Current
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 45 registered trials. It describes the research record, not a recommendation.

Identity
NameCagrilintide (AM833)
Chain length—
Molecular weight4,409 Da
FormulaC194H312N54O59S2
Structure typeNot established
ClassMetabolic
Research levelExtensively Studied
Discovered byCurated master list · 2026

Mass and formula from PubChem CID 171397054. No verified residue count for this compound.

Pharmacology
MechanismLong-acting amylin analog
RouteSubcutaneous injection
Half-life~7–8 days
Time to peak—
DurationWeekly dosing (investigational)
Extraction confidence0.70
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Sep 4, 2026. How this works →
Research stats
Total studies19
Human / animal / cellular4 / 1 / 0
Highest trial phasePhase 3
Years covered2021–2026
Latest study18d ago
Publication history
20212026
Research funding
—no NIH grants found
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

19 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
Weight Loss, Obesity Medication, and Risk of Obesity-Associated Cancer: A Meta-Analysis of Randomized Controlled Trials.
FindingCoagonists RR=0.43, 95% CI: 0.19 to 0.97
review2026Full text read0.80
Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.
Finding112,511 participants across 69 studies.
review2026Full text read0.90
Maximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials.
FindingMD = -13.99 kg vs placebo; 95% CI = -18.38 to -9.61; p < 0.00001
review2026Full text read0.90
Current and forthcoming pharmacotherapies for adolescent obesity: Evidence-based review.
FindingSemaglutide reduces body mass index by 16.1%.
review2026Full text read0.70
Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo.
Finding-6.08% body weight, -5.89 kg with Cagrilintide monotherapy
review2026Full text read0.90
Beyond GLP-1: Amylin-Based Pharmacotherapy and the Search for Better-Tolerated Weight-Loss Drugs.
TakeawayAmylin-based therapies like cagrilintide offer a promising approach to obesity treatment, but understanding their tolerability is key to enhancing clinical utility.
review2026Full text read0.80
Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial.
Finding24 [24%] of 99 participants in the zalfermin 30 mg plus semaglutide 2·4 mg group improved in liver fibrosis vs 16 [16%] of 100 participants in the placebo group; p=0·19.
Human2023Full text read0.80
Distinct brain regions mediate regulation of food intake in response to GIPR agonism or antagonism.
FindingNot reported in abstract.
Animal2023Partial text0.60
Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1.
Finding30.3% achieved BMI < 27 kg/m² and WHtR < 0.53 with CagriSema at week 68.
Human2023Full text read0.70
Cagrilintide-semaglutide: a new option for patients with type 2 diabetes.
TakeawayNot reported in abstract.
—2026Title only0.10
Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.
FindingMean HbA1c change was significantly greater with cagrilintide-semaglutide (2.4 mg each) versus semaglutide 2.4 mg (-1.91 percentage points vs -1.75 percentage points; p=0.0035).
Human2024Full text read0.90
Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.
Finding-1.7 percentage points (95% CI -2.0 to -1.3; p<0.0001) treatment difference for cagrilintide-semaglutide (2.4 mg each) vs placebo.
Human2024Full text read0.90

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Cagrilintide (AM833) will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Cagrilintide (AM833) is discussed should be drawn from it.

Articles mentioning Cagrilintide (AM833)